扎那米韦
神经氨酸酶
奥司他韦
神经氨酸酶抑制剂
医学
内科学
病毒
药品
病毒学
免疫学
药理学
疾病
2019年冠状病毒病(COVID-19)
传染病(医学专业)
作者
Haruka Hishiki,Naruhiko Ishiwada,Sachiko Naito,Koo Nagasawa,Tomohiro Someya,Nobue Inoue,Mana Haraki,Tomomichi Kurosaki,Yousuke Kameoka,Kazuo Suzuki
出处
期刊:PubMed
[National Institutes of Health]
日期:2015-12-01
卷期号:68 (6): 337-43
摘要
We investigated the clinical symptoms of 206 pediatric patients with influenza virus infection and compared them among oseltamivir-treated, zanamivir-treated, and laninamivir-treated groups in 2013/2014 influenza season. The drug compliance of each neuraminidase inhibitor was good in all three groups. Although the duration of fever after administration of the first dose of each neuraminidase inhibitor were significantly prolonged in the patient with influenza B infection than in the patient with influenza A infection, no statistically significant difference in the clinical efficacy and the side effect among three groups were found. The number of biphasic fever episodes in patients treated with neuraminidase inhibitor was rare (two episodes of oseltamivir-treated group and one episode of zanamivir-treated group). In conclusion, under the good drug compliance, the efficacy of all three neuraminidase inhibitor was the same for the treatment of influenza virus infection in children.
科研通智能强力驱动
Strongly Powered by AbleSci AI